This webinar provided a unique opportunity for the antibiotic community. The Innovative Medicines Initiative’s GNA NOW Consortium was looking for a novel antibiotic compound to progress to a clinical candidate and informed participants about what was in it for interested candidates, and how to submit a proposal, among others.
About GNA NOW
Established in July 2019, the GNA NOW Consortium is a European collaboration of 11 partners focused on progressing Gram-Negative antibiotics from lead optimization to the completion of Phase I trials. Working under the AMR Accelerator umbrella, the project is funded by the Innovative Medicines Initiative (IMI) with in kind contributions from industry partner, Evotec.
This project has received funding from the Innovative Medicines Initiative 2 Joint Undertaking under grant agreement No 853979. This Joint Undertaking receives support from the European Union’s Horizon 2020 research and innovation programme and EFPIA.
This communication reflects the views of the GNA NOW Consortium and neither IMI nor the European Union and EFPIA are liable for any use that may be made of the information contained herein.
For questions regarding registration, feel free to contact the GNA NOW programme office at: email@example.com